An observational study for evaluating prescription pattern of drugs, adverse drug reactions in paediatric acute lymphoid leukaemia in a tertiary care hospital
DOI:
https://doi.org/10.18203/2320-6012.ijrms20242618Keywords:
Alopecia, Methotrexate, Paediatric ALL, VincristineAbstract
Background: Prescription research analyses trends in prescribing drugs as per rational therapeutics principles and if any deviations found helps in providing vital feedback to physicians. Recent advances in cancer chemotherapy has improved survival rates in Acute Lymphoblastic Leukaemia (ALL), but the adverse drug reactions adds to disease burden, also compromises quality of life. There is paucity of data on prescription audit, adverse drug reactions in paediatric ALL, hence the study was planned.
Methods: Study was cross-sectional prospective audit. After IEC approval, written informed consent were taken from 156 prospective ALL patients aged 1-15 years (completed one cycle of induction phase). The variables assessed were WHO prescribing indicators, completeness. The details of adverse drug reactions-type, severity, preventable; causality assessment (WHO-UMC, Naranjo Scales). Analyzed by descriptive statistics [Microsoft Excelv16.0].
Results: Out of total 156 prescriptions (2576 drugs prescribed), total drugs per prescription was 16. Most of the drugs were prescribed by generic name (97.94%). Commonest anticancer drug prescribed in regimen was vincristine, methotrexate. Most common supportive medication class were antiemetic, antacid, antiulcer. 100% prescriptions were complete for anticancer drugs, 66% for supportive care medications. Most common ADR found was alopecia (100%), febrile neutropenia (31.41%) and fatigue (30.76%). Majority ADR were possibly (93.81%) related to treatment. 37.97% ADR were of moderate severity, 100% ADRs were not preventable.
Conclusions: The commonest anti-cancer drugs prescribed are vincristine, methotrexate and supportive care prescribed is antiemetic therapy (granisetron). The frequent adverse drug reaction found was alopecia, febrile neutropenia.
References
Wu Y, Deng Y, Wei B, Xiang D, Hu J, Zhao P, et al. Global, regional, and national childhood cancer burden, 1990–2019: an analysis based on the global burden of disease study 2019. J Adv Res. 2022;40:233-47.
Agrawal S, KP. National comprehensive cancer network guidelines for pediatric acute lymphoblastic leukemia. Ind Paediatr. 2020;57(6):561-4.
Kumar V, Abul K, Abbas JCA. Robbins basic pathology. 10th ed. James A. Perkins (Illustrator), editor. Philadelphia, PA: Elsevier - Health Sciences Division; 2017:431-432.
National Cancer Institute. Childhood acute lymphoblastic leukemia treatment (PDQ®)–health professional version. NCI. Available at: https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq#_2077. Accessed 21 February 2023.
Das N, Banavali S, Bakhshi S, Trehan A, Radhakrishnan V, Seth R, et al. Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India. Trials. 2022;23(1):1-20.
Diba F, Karim A, Soma SA, Chowdhury I, Mamun S, Mondal NI. Immunophenotypic pattern and treatment outcome after completion of induction remission in children with acute lymphoblastic leukemia. J Curr Advan Medi Res. 2021;8(1):59-64.
Zawitkowska J, Lejman M, Zaucha-Prazmo A, Drabko K, PŁonowski M, Bulsa J, et al. Grade 3 and 4 toxicity profiles during therapy of childhood acute lymphoblastic leukemia. In Vivo (Brooklyn). 2019;33(4):1333-9.
Manjesh PS, Shetty YC, Chinnaswamy G, Patankar PS. Prescription pattern of drugs in pediatric cancer patients in a tertiary care hospital: An observational study. Oncol J India. 2021;5(2):76.
Cartwright RA, Gurney KA, Moorman A V. Sex ratios and the risks of haematological malignancies. Br J Haematol. 2002;118(4):1071-7.
Pearce MS, Parker L. Childhood cancer registrations in the developing world: still more boys than girls. Int J cancer. 2001;91(3):402-6.
Figure Mum-1 Population Pyramid showing Age Distribution: 2012 Mumbai. Available at: https://main.icmr.nic.in/sites/default/files/reports/Mumbai_Ann.pdf. Accessed 19 February 2023.
Challinor JM, Hollis R, Freidank C, Verhoeven C. Educational needs and strategies of pediatric oncology nurses in low- and middle-income countries. An International Society of Pediatric Oncology- Pediatric Oncology in Developing Countries Nursing Working Group Initiative. Cancer Nurs. 2014;37(4):E36-47.
Mathaiyan J, Jain Tanvi, Dubashi Biswajit, Reddy Satyanaryana BG. Prescription errors in cancer chemotherapy: Omissions supersede potentially harmful errors. J Pharmacol Pharmacother. 2015;6(2):83-7.
Karuna SP. Pulse therapy-a newer approach. Dentistry. 2017;7(1):41-4.
Rives S, Estella J, Gómez P, López-Duarte M, de Miguel PG, Verdeguer A, et al. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative G. Br J Haematol. 2011;154(5):600-11.
Siddique R, Hafiz MG, Rokeya B, Jamal CY, Islam A. Ondansetron versus granisetron in the prevention of chemotherapy induced nausea and vomiting in children with acute lymphoblastic leukemia. Mymensingh Med J. 2011;20(4):680-8.
American Cancer Society. Non-opioids and other drugs used to treat cancer pain. Available at: https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/pain/non-opioids-and-other-drugs-to-treat-cancer-pain.html. Accessed 01 March 2024.
Podpeskar A, Crazzolara R, Kropshofer G, Obexer P, Rabensteiner E, Michel M, et al. Supportive methods for childhood acute lymphoblastic leukemia then and now: A compilation for clinical practice. Front Pediatr. 2022;10:980234.
Vázquez-Cornejo E, Morales-Ríos O, Hernández-Pliego G, Cicero-Oneto C, Garduño-Espinosa J. Incidence, severity, and preventability of adverse events during the induction of patients with acute lymphoblastic leukemia in a tertiary care pediatric hospital in Mexico. Plos one. 2022;17(3):e0265450.
Seruga B, Sterling L, Wang L, Tannock IF. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J Clin Oncol. 2011;29(2):174-85.
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49(9):2229-32.
Sharma A, Kumari M, Manohar Diana BK. Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care hospital in South India. Perspect Clin Res. 2015;6(2):109-15.
Chopra D, Rehan H, Sharma V, Mishra R. Chemotherapy-induced adverse drug reactions in oncology patients: A prospective observational survey. Indian J Med Paediatr Oncol. 2016;37(1):42-6.
Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27(6):538.
